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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality,
poor prognosis, and palliative treatments, due to the rapid upregulation of alternative compensatory
pathways and desmoplastic reaction. miRNAs, small non-coding RNAs, have been recently identified
as key players regulating cancer pathogenesis. Dysregulated miRNAs are associated with molecular
pathways involved in tumor development, metastasis, and chemoresistance in PDAC, as well as
other cancers. Targeted treatment strategies that alter miRNA levels in cancers have promising potential as therapeutic interventions. miRNA-345 (miR-345) plays a critical role in tumor suppression
and is differentially expressed in various cancers, including pancreatic cancer (PC). The underlying mechanism(s) and delivery strategies of miR-345 have been investigated by us previously.
Here, we summarize the potential therapeutic roles of miR-345 in different cancers, with emphasis
on PDAC, for miRNA drug discovery, development, status, and implications. Further, we focus on
miRNA nanodelivery system(s), based on different materials and nanoformulations, specifically for
the delivery of miR-345.
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1. Pancreatic Cancer

published maps and institutional affil-

Cancer is one of the leading causes of death globally, acting as a crucial barrier to
enhancing life expectancy, with 19.3 million worldwide new cancer incidence accounts and
10 million cancer deaths in 2020 [1]. Pancreatic cancer (PC) is the fourth-highest cause of
cancer mortality, with an overall 10-year survival of less than 1% and 5-year survival rate
of less than 3%, based on statistics of patients from England and Wales [2,3]. In 2020, PC
accounted for 0.49 million (2.6%) new cases and 0.46 million deaths (4.7%) worldwide [1].
PC accounts for about 3% of all cancers and about 7% of all cancer deaths in the USA [4].
A study of 28 European countries showed that PC would surpass breast cancer as the third
leading cause of cancer deaths by 2025 [5].
Pancreatic ductal adenocarcinoma (PDAC) neoplasms that arise from the duct of the
exocrine pancreas account for >90% of PCs and contribute to major medical complications.
In contrast, PCs that arise from the endocrine gland (pancreatic neuroendocrine tumors
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(NETs)) are less common (<5%). It is estimated that 1 in 64 individuals will develop PDAC,
an age-related neoplasm, with an average age at diagnosis of about 71 yrs [6]. With many
developed countries facing aging populations, PC incidence level is expected to rise over
the coming years and be the second leading cause of death in the US by 2030 [7,8]. PDAC
is an aggressive disease that invades the lungs, liver, peritoneal cavity, lymph nodes, and
intestines [9]. Symptoms including abdominal pain, weight loss, bloating, nausea and
vomiting, new-onset diabetes, back pain, shoulder pain, pruritus, dyspepsia, lethargy,
jaundice, and changes in bowel habits, developed during PDAC, are often neglected by the
patients [10].
The modifiable risk factors associated with PC are (i) smoking, with a strong association of 74% increased risk in current smokers and a 20% increased risk in former smokers;
(ii) alcohol, with a 15–43% increased risk based on meta-analysis; (iii) obesity, with a 10%
increased risk for every 5 BMI units (body mass index); (iv) dietary factors, with a nonsignificant positive association for red meat and a 17% increased risk associated with 50 g/d
of processed meat consumption, compared to 20 g/d; and (v) the presence of Helicobacter
pylori, with a 45% increased risk [11]. Several DNA mismatch repair genes, which include
MLH1, MSH2, MSH6, and PMS2, have been reported to be associated with an increased
incidence of PDAC [12]. Familial atypical multiple moles-melanoma syndromes (CDKN2A
gene mutation), and hereditary pancreatitis (PRSS1 and SPINKI genetic abnormalities) are
also associated with an increased risk of PDAC [13,14]. There is also an immense increased
risk of PDAC associated with germline mutation of ovarian and breast cancers (PALB2 and
BRCA1/BRCA2, respectively), as alterations in germline BRCA and PALB2 are detected in
approximately 5–9% of patients with PDAC and can lead to homologous repair deficiency
(HRD) [15].
Although substantial progress has been made in developing many novel cancer therapies, PC survival rates have been static in the last 4 decades, and cytotoxic therapies
and their combination with targeted therapies for cancer-associated molecular pathways
have not shown adequate results [2]. This is mainly due to (1) the asymptomatic nature
of PDAC, (2) lack of specific tumor markers and late-stage diagnosis of the disease, (3)
the retroperitoneal position of the pancreas, which limits the imaging capacity to detect
this disease at its early stages, (4) PDAC’s high chemotherapy resistance and broad heterogeneity of genetic mutations, (5) a dense stromal environment, (6) rapid upregulation
of alternative compensatory pathways, and (7) a majority of patients with unresectable,
locally advanced, or metastatic disease at the time of diagnosis [16–18], contributing to poor
prognosis and dismal surval rates. These factors indicate that if PC is diagnosed earlier,
there is a significantly improved chance of disease control with effective treatment [2].
More than two-thirds of PC cases found are associated with diabetes mellitus (DM), linked
with increased metastasis in PC patients and an increased inflammatory response, with
high glucose levels stimulating PC progression [19]. Previous reports have also shown an
increased risk of PC in type 2 DM patients [20].
Current available therapeutic options for PC are surgery, radiation, chemotherapy,
immunotherapy, and targeted therapy [21]. Most of the available treatments are palliative, to relieve disease-related symptoms and prolong survival. Recently, targeting major
cancer pathways using microRNAs (miRNAs) has shown a potential therapeutic option
for cancer treatment due to their ability target more than 200 genes, as reported in our
previous studies [22,23]. Thus, inhibition (oncomiRs) or replacement (tumor suppressors)
of microRNAs is a promising area of study for therapeutics. PC has several challenges,
in terms of diagnosis, treatment, and prognostic outlook. This review will explore how
miR-345 and its effective delivery can play a significant role in disease screening, prognoses,
and new therapeutic options.
2. PC and miRNA
There is an urgent need to identify novel diagnostic/therapeutic targets for the effective management of highly malignant PC [18]. miRNAs have received significant attention
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as a new class of non-coding-RNAs engaged in the regulation of gene expression. It is now
evident that miRNAs exhibit differential expression in cancer and play essential roles in
the disease processes [24]. Biosynthesis of miRNA is a multi-step process, which involves
both cytoplasmic and nuclear components. First, RNA polymerase II transcribes miRNA
into longer primary transcripts (pri-mRNA) of several hundred kilobases in length. These
transcripts have 50 7-methyl guanylate (m7G) cap structure and 30 poly(A) tail, and two mature endonuclease reactions (in the nucleus by Drosha/DGCR8, a ribonuclease III (RNase
III) endonuclease that cleaves the pri-miRNA into a 65–70 bp stem-loop precursor miRNA
(pre-miRNA)). The pre-miRNA is then transported to the cytoplasm by an exportin-5–
RanGTP-dependent mechanism. Further, in the cytoplasm, the pre-miRNA is processed to
generate mature 19–24 bp RNA duplex by RNase III endonuclease, Dicer/TRBP, and AGO2.
Then, this RNA duplex unwinds and matures to a single-stranded miRNA (one of the
strands) by the helicase activity. Further, it enters into the RNA-induced silencing complex
(RISC) and directs the complex to target mRNA, through a poorly defined mechanism. It is
extremely rare to have a perfect base pair binding of miRNA and the genes, but a strong
base-pairing between the 50 half of the miRNA (2–8 nucleotides) mediates the mRNA
regulation in animals [25]. Any complementarity between the seed region of miRNA and
30 UTR region of the target gene leads to translation inhibition. Hence, one miRNA is
predicted to target more than 200 genes, on average coordinating multiple pathways, and
regulating the critical processes of gene activation and suppression. This diverse role leads
to the complexity of gene regulation, thus mediating complex cell function networks, such
as cell proliferation, differentiation, apoptosis, and organ development [26].
Different patterns have been found in miRNA expression profiles in PC, which have
contributed to the development of a miRNAome between the normal and cancerous
pancreas [2]. Determination of these miRNA expression profiles has been made possible
through different gene profiling methods, mainly microarray, RNA-sequencing, and RTPCR analysis of specimens [27]. Due to the stability of miRNA in circulation, blood
screening could be employed to detect specific miRNA linked with stage, survival rate, or
aggressiveness of the disease [28]. Previous studies have demonstrated the potential of
miR-483-3p and miR-21 as biomarkers of PDAC from blood plasma. The plasma expression
of both miR-483-3p and miR-21 was found to be significantly higher in PDAC patients,
compared to healthy controls (p < 0.01), while these miRNA expression levels correlated
with overall lower survival in those patients with PDAC (p < 0.01) [29]. Indeed, miR-375
was suggested to be linked with islet cells, as the expression was high in normal pancreatic
tissues, compared to the cancerous and inflammatory tissues, with a complete absence in
representative cell lines. The serum carbohydrate antigen 19-9 (CA-19-9) been employed as
a marker for assessing clinical treatment efficacy in PC. Limitations associated with CA 19–9
include ineffectiveness, low sensitivity, and specificity, yet it is still the only FDA approved
marker in PC [29]. miRNAs that are specific to cancer types can be identified for early
screening, and miRNAs could be used for diagnostic purposes, as they are stable in serum,
ease the non-invasive detection in circulation, and provide a convenient screening method
for miRNA detection. Among the top aberrantly expressed miRNAs in cancer samples,
miR-424, miR-100, miR-301, miR-212, and miR-125b-1 were overexpressed, whereas miR345, miR-142-P, and miR-139 were underexpressed, relative to normal pancreatic samples.
Additionally, miR-221, miR-376a, and miR-301 were found to be localized within the tumor
cells, rather than other cells in the stroma [30].
The miRNAs miR-141, miR-148a, miR-200a, miR-200b, miR-200c, miR-216, miR-217,
and miR-375 exhibited high expression levels, and miR-133a, miR-143, miR-145, and miR150 exhibited low expression levels within normal pancreatic tissue, compared to 33 other
human tissues [31]. Upregulated miR-372, miR-146a, miR-204, miR-10a, and miR-10b
were also detected in PC cell lines (CAPAN-1 and CFPAC-1), compared to human normal
pancreatic ductal epithelial cells (HPDE), with changes of greater then 10-fold. miR-93,
miR-196a, miR-196b, miR-203, miR-205, miR-210, miR-221, miR-222, and miR-224 were
upregulated only in cancerous tissues and cell lines. Interestingly, a complete absence of
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miR-196a and miR-196b was observed in normal and pancreatitis tissues [32]. This gives a
potential selectivity to PC. The upregulation of miR-155, miR-203, miR-210, and miR-222, as
well as the downregulation of miR-216 and miR-217, are associated with poorer prognosis
and overall survival [33]. Among these miRNAs, miR-345 has been gaining attention, due
to its involvement in mediating signaling pathways and crosstalk in PDAC and PC, as well
as other cancer types. Therefore, the following section will focus on the implications of
miR-345 in multiple human malignancies, where PDAC would be given special emphasis.
3. Role of miR-345 in Pancreatic Cancer
miR-345 is a small, non-coding RNA, located at human chromosome 14q32.2, that is
reported to have dynamic roles in various human pathologies. Differential expression of
miR-345 has been reported in the blood and tissues of multiple human malignancies, such
as pancreatic ductal adenocarcinoma (PDAC), gastric cancer (GC), colorectal carcinoma
(CRC), prostate cancer (PCa), and breast cancer (BRCA) [33]. This differential regulation
of miR-345 has been correlated with excessive cell proliferation, invasion, and migration,
which are characteristics of cancer development and metastasis. Recent research has gained
much attention, implicating the role of miR-345 in various human pathologies [34].
Epithelial-mesenchymal transition (EMT) is a biological switch that involves the transdifferentiation of epithelial cells attached to the basement membrane and is characterized
by apical-basal polarity. Increased mesenchymal phenotypes with spindle-shaped appearance, invasiveness, and enhanced migratory capacity ultimately lead to the demolition
of the basement membrane [33]. EMTs occur during various biological processes and
are classified into three types: the first type occurs during embryonic development; the
second type is associated with adult tissue regeneration; and the third type occurs in
cancer progression [35]. Numerous cellular signaling pathways and their crosstalk in the
regulation of transcription factors and ultimately trigger EMT in cancer [36]. miR-345 is
one the most critical miRNAs that helps to mediate the metastasis signaling pathways of
EMT [37]. Studies have found that miR-345 can regulate the upstream and downstream
molecules of PI3K/AKT, mTOR, and YAP/TAZ signaling [38–40] (Figure 1).
Previously, miR-345 was identified as one of the most significantly downregulated
miRNAs in PC; however, its functional significance remained unexplored. One study
showed that downregulation of miR-345 was a frequent event in PC, and this downregulation significantly correlated with PC progression [41]. Further, ectopic expression of
miR-345 in PC cells dramatically reduced cell growth and induced apoptosis [22].
Srivastava et al. showed that miR-345 can induce apoptosis in caspase-dependent
and -independent mechanisms in PC cells. They also observed downregulated miR-345
expression in PC tissues and cell lines. They further demonstrated that the overexpression
of miR-345 disrupted mitochondrial membrane potential in PC cells, resulting in the release
of cytochrome C (Cyt c) to the cytosol from the mitochondria, causing the activation of
Caspase 3 and 7 with subsequent cleavage of poly [ADP-ribose] polymerase 1 (PARP-1)
(Figure 1). Additionally, overexpressed miR-345 induced the translocation of the apoptosisinducing factor (AIF-1) to the nucleus, leading to caspase-independent apoptosis. Their
experiments identified B-cell lymphoma 2 (BCL2), an anti-apoptotic molecule, as the
direct target of miR-345. The authors considered the miR-345 downregulation-mediated
upregulation of BCL2, the switch that triggered the observed apoptosis resistance in PC [42],
(Figure 1).
Apoptosis is a vital tool that assists in biological events, such as tissue homeostasis, tissue development, and immunity. Dysregulation of apoptosis is often associated
with tumorigenesis [43]. The primary event in apoptosis is the loss of the mitochondrial
membrane potential, which ultimately results in mitochondria-mediated apoptosis [44].
Cyt C is released, in response to the changes in mitochondrial membrane potential, binding
with apoptotic protease activating factor-1 (APAF-1) and ATP (adenosine triphosphate),
resulting in the formation of a complex. This complex binds to pro-cas-9, which, in turn,
causes the cleavage of it and activation of Cas-3 and 7 (effector caspases). Once formed,
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these effector caspases cleave PARP-1 and mediate caspase-dependent apoptosis [45]
(Figure 1). In the case of caspase-independent apoptosis, AIF, from the inter-mitochondrial
membrane space, translocates to the nucleus, which results in chromatin condensation,
nuclear fragmentation, and, subsequently, cell death [46].

Figure 1. Schematic representation of the role of miR-345 in different cancer types.

Previous research has shown an increase in the level of BCL2 in numerous cancer
types, including PC, and is associated with apoptosis resistance and cancer metastasis [47].
BCL2 regulates the mitochondrial release of Cyt c and AIF, which favor cell survival. Thus,
the downregulation of BCL2 by miR-345 holds significance in PC therapy. Tzifi et al. further
detail the blockage of the Cyt c release, in response to the overexpression of BCL2, and
associated abolishment of apoptosis process [48] (Figure 1).
Srivastava et al. also showed that miR-345 is differentially expressed in PC cell
lines, with more downregulated expression in poorly differentiated cancer cells. Ectopic
overexpression of miR-345, in two poorly differentiated PC cell lines, Panc1 and MiaPaCa,
diminished their growth, clonogenicity, motility, and invasion and enhanced cell–cell
interaction. miR-345-overexpressing cells had distinguishable morphological differences
and increased epithelial marker (E-cadherin) expression, as well as loss of mesenchymal
(N-cadherin, vimentin, twist, slug, and snail) markers expression, as compared to the
control cells. Further, the data showed that miR-345 overexpressing PC cells were more
sensitive to gemcitabine (GEM), as compared to the control cells. Altogether, these findings
demonstrate novel tumor suppressive roles of miR-345 in PC and indicate that miR-345
downregulation may be one of the mechanisms underlying the chemoresistance of PC [42]
(Figure 1).
Another study by Mou et al. showed that the downregulated expression of miR-345
in PDAC tissues and cells, and the overexpression of miR-345 in PANC1 and SW1990
cell lines in vitro inhibited proliferation and metastasis by inactivating the nuclear factor
κB (NFκB) signaling pathway and further suppressed PC progression [49]. Constitutive
activation of NFkB signaling has been reported in approximately 70% of PDAC cases [50].
NFκB is an important transcription factor (TF) that has been widely researched, in the
context of inflammation. Constitutive or induced activation of this transcription factor is
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the key to inflammation-driven carcinogenesis [51]. NFκB operates either by canonical or
non-canonical pathways, and the activity of this TF is tightly regulated by the inhibitors
of κB (IκB). These inhibitory κB molecules mask the nuclear localization signal (NLS) and
thereby sequester the latent NFκB molecule in the cytoplasm [52]. Phosphorylation of
IκB molecules by inhibitory κB kinase (IKK), in response to cellular stimuli, results in the
ubiquitination and proteasomal degradation of IκB, allowing NFκB to enter the nucleus
and regulate the target gene expressions associated with cell cycle regulation, proliferation,
apoptosis, inflammation, and cancer metastasis [53]. CCL8 (Chemokine C-C motif Ligand
8/MCP2), a cytokine of CC chemokine family, interacts with numerous cell-signaling
receptors, regulates and controls leukocyte chemotaxis, and attracts tumor-associated
macrophages, inflammatory diseases, and HIV entry [54]. The dynamic role of CCL8
in tumor progression and invasion, by activating NFκB signaling, is widely accepted in
different cancer types [55]. CCL8 has been identified as the direct target of miR-345 in
PDAC. Further, the overexpression of miR-345 resulted in a low level of CCL8 that, in turn,
reduced the nuclear protein level of NFκB and subsequent inhibition of proliferation and
migration of PDAC cells. These results suggest that miR-345-5p potentially inhibits PDAC
progression by inactivating NFκB signaling [49] (Figure 1).
Restoration of miR-345 in PC cell lines resulted in the inhibition of growth, motility,
invasion, and upregulation of epithelial markers [42]. At the molecular level, the ectopicexpression of miR-345 in PC cell lines led to significant downregulation of SHH, MUC4,
Kras, C-Myc, CSC, and survival markers, as well as the upregulation of cleaved caspase
7 & 3 and PARP (Figure 1). Sonic hedgehog (Shh) and MUC4 signaling pathways play an
essential role in tumor growth and metastasis by promoting EMT, PC stem cells, angiogenesis, and desmoplasia, which limit the delivery and efficacy of chemotherapy [56–58].
Therefore, miR-345 is an excellent candidate for diagnostic/prognostic and therapeutic
targets in PC.
4. Role of miR-345 in Other Cancer Types
4.1. Colon and Rectal Cancer
Schou et al. studied the role of miRNA in colorectal cancer (CRC), aiming to find
miRNA expression profiles in whole blood that were prognostic for overall survival (OS) in
patients with metastatic colorectal cancer (mCRC) treated with cetuximab and irinotecan.
Interestingly, they found that miR-345 was the strongest prognostic miRNA, significant in
the full cohort and non-KRas mutant population, as well as in progression-free survival
(PFS). Thus, miR-345 in whole blood was a potential single prognostic biomarker for a
clinical outcome for OS in all patients. In addition, high miR-345 expression was associated
with a lack of response to treatment with cetuximab and irinotecan [59].
Another study, by Tang et al., shows how aberrant methylation of miRNAs is found
to be deregulated in human CRC. They also investigated CpG island promoter hypermethylation, as a potential mechanism underlying miRNA disruption, and identified
methylation-sensitive miRNAs that might repress CRC development. Comparative differential expression of miRNAs post-treatment with 5-aza-20 -deoxycitidine (5-aza-dC) was
studied using microarrays, and it was found that the expression of miR-345 was significantly
down-regulated in 51.6% of CRC tissues, compared with normal tissues. DNA methylation
analyses of miR-345 showed high methylation levels in tumors versus normal tissues. Low
expression of miR-345 was associated with lymph node metastasis and a worse histological
type. Increased miR-345 function was sufficient to suppress colon cancer cell proliferation and invasiveness in vitro. Furthermore, they also demonstrated that BCL2-associated
athanogene 3 (BAG3), an anti-apoptosis protein, is a target of miR-345. These results suggested that, as a methylation-sensitive miRNA in CRC, miR-345 may play an important role
of antineoplastic as a growth inhibitor in CRC development [37] (Figure 1).
Few reports to date have investigated the association between circulating miRNA
signatures and preoperative chemoradiotherapy (pre-CRT) pathological response in rectal
carcinoma. Pre-CRT has been represented as the standard treatment for locally advanced
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rectal cancer (LARC), but significant variations of tumor radiation response to CRT have
been reported in the clinic. Global miRNA expression was assessed in CRT-sensitive and
-resistant groups and it was observed that miR-345 was significantly elevated in the CRTresistant group. High miR-345 expression was significantly correlated with an unfavorable
pre-CRT pathological response in tissue and serum, acting as a promising biomarker [60]
(Figure 1).
4.2. Gastric Cancer
Feng et al. showed that miR-345 expression was decreased, in the case of gastric cancer
(GC) cell lines (SGC-7901, AGS, MKN-45, MGC-803) and tissues. Reduced expression of
miR-345 was associated with the occurrence of lymph node metastasis and advanced TNM
(tumor (T), nodes (N), and metastases (M)) stages in GC patients. Low expression levels
of miR-345 have shown reduced overall survival (OS) and disease-free survival (DFS) in
GC patients. They also showed that miR-345 knockdown could promote lung metastasis,
through induction of the EMT phenotype and by repressing the expression of E-cadherin,
an epithelial marker, which resulted in an aggressive phenotype of GC cells in nude mice.
In addition, they showed that miR-345 could inhibit the epithelial-mesenchymal transition
of GC (Figure 1).
Further, Forehead box Q1 (FOXQ1) was confirmed to be the downstream target of
miR-345 in GC cells. FOXQ1 is a member of the forehead box protein family, which
functions as a transcription factor, associated with the regulation of cell differentiation and
metastasis [61,62]. FOXQ1 binds to the E-box present at the promoter region of E-cadherin
and represses its expression, thus resulting in EMT and its associated enhanced migratory
capacity of the cells [62]. FOXQ1 could reverse the inhibitory effects of miR-345 on GC
metastasis, while knockdown prevented the promoting effects of miR-345 knockdown
on GC metastasis [63] (Figure 1). This study demonstrates that miR-345 is a promising
biomarker and therapeutic target in GC. The functional relevance of FOXQ1 in multiple
human cancers, such as gastric cancer, esophageal cancer, PDAC, carcinoma of the breast,
carcinoma of lung, adenoma, and carcinoma of the intestine, has been appreciated in the
recent scientific literature [61,64–67].
4.3. Prostate Cancer
The role of miR-345 in prostate cancer (PCa) was studied by Tinay et al., where they
compared under expression in PCa with normal patients. They discovered that miR-3455p were significantly overexpressed in serum from prostate cancer patients and further
demonstrated that miR-345-5p (Two mature miRNA species may be generated from the
50 [-5p] and 30 [-3p] arms of a pre-miRNA precursor. In most cases, only one species remains
while the complementary species is degraded. To avoid further confusion and ambiguity
by prematurely presuming expression levels and biological functions, a specific miRNA
strand has been represented), promotes CRPC (Castration-Resistant PCa) cell growth and
migration in vitro and validated CDKN1A (the gene encoding p21) as the direct target.
Thus, circulating miR-345-5p can be used as a biomarker for PCa diagnosis and therapeutic
response. CDKN1A inhibits the cyclin/CDK complex that, in turn, leads to cell cycle
inhibition, ultimately resulting in cancer suppression. The oncogenic roles of miR-345-5p,
through targeting CDKN1A, render it a potential therapeutic target for PCa [68] (Figure 1).
Another study by Chen et al. showed that overexpression of miR-345 in prostate cancer
cells suppressed proliferation, migration, and invasion. Using a xenograft tumor (athymic
nude mouse) model, they revealed that miR-345 inhibits the growth of prostate cancer cells
both in vivo and in vitro. Furthermore, they identified and validated Smad1 as a direct
target of miR-345 [69].
4.4. Lung Cancer
The role of miR-345 in lung cancer was studied by Zhang et al., where they showed
that prominent downregulation was associated with the patient poor prognosis in non-
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small-cell lung carcinoma (NSCLC) tissue specimens [70]. They also found that miR-345
overexpression could dramatically inhibit NSCLC cell migration and invasion. Further,
the study also identified Yes-associated protein 1 (YAP1) as the direct functional target of
miR-345 in NSCLC cells, as YAP1 expressions were negatively correlated with the miR-345
in NSCLC tissue samples. Moreover, YAP1 was found to be involved in the functions
of miR-345 in inhibiting NSCLC cell invasion and migration [70] (Figure 1). YAP1, an
oncogenic transcriptional coactivator, has recently been identified as a molecular target
for tumor therapy. YAP1 is implicated in regulating multiple cellular processes, including
cell apoptosis, proliferation, growth, tumorigenesis, stem cell differentiation, and renewal.
Wang et al. (2012) identified five miRNA (miR-93, miR-100, miR-134, miR-151, and miR-345)
signatures significantly associated with overall survival and can predict patient survival
in advanced stages of NSCLC. High expression of miR-100 and low expression of miR-93,
miR-134, miR-151, and miR-345 were associated with poor survival outcomes. These
findings may have implications in the understanding of advanced NSCLC [71]. Overall,
miR-345 expression was downregulated in NSCLC, and its low expression was correlated
with malignant clinical parameters and poor prognosis [72].
4.5. Liver Cancer
Jiang et al. showed that hepatocellular carcinoma (HCC) patients with good survival
rates had high miR-345 expression levels, compared with expression in cases with poor
survival rates [73]. Shiu et al. reported that hepatitis C virus (HCV) core protein upregulated the expression of miR-345, which inhibited curcumin-induced apoptosis by targeting
p21 in Huh7 cells [74]. Another study by Yu et al. showed that miR-345 underexpression was observed in HCC tissues and cells and illustrated that the loss of miR-345 promoted HCC cell migration and invasion and resulted in epithelial-mesenchymal-transition
(EMT) progression, probably by targeting interferon regulatory factor 1 (IRF1)-mediated
mTOR/STAT3/AKT signaling in vitro. It was found that the mTOR/STAT3/AKT pathway
and its downstream targets, including Slug, Snail, and Twist, may be involved in the
IRF1-mediated EMT process (Figure 1). Their work provided the first evidence for miR-345
in prognosis and treatment in HCC [40].
Ding et al. explored the role of miRNA in liver cancer, showing that miR-101 can
reduce the level of hepatitis B virus (HBV) replication and inhibit the proliferation of
hepatoma cells. In addition, they also found miR-345 can upregulate the level of HBV
replication and promote the proliferation of liver cancer cells [75]. Hepatitis B is a major
infectious disease worldwide, chiefly caused by the HBV infection, where HBV enters
hepatocytes and destroys their DNA, causing cirrhosis of the liver that, in some cases,
develops into liver cancer [76,77]. A recent study by Zhang et al. (2017) showed that YAP1
had been identified as the direct functional target of miR-345 in HCC. Under-expression
of miR-345 was linked with poor prognosis, with reduced miR-345 expression in HCC
tissues and cell lines (MHCC-97H, HEP3B) [78] (Figure 1). miR-345 overexpression was
shown to greatly reduce the migratory and invasive properties of MHCC-97H. Knockdown
of miR-345 exhibited an enhanced lung metastasis of HCC cells in vivo and Hep3B cells
in vitro, respectively. At the same time, overexpression and knockdown of YAP1 reversed
the entire condition. YAP1 is a downstream molecule of hippo signaling, increasingly
reported in the aspect of cancer progression and metastasis [79]. YAP/TAZ elevates specific
genes such as CDK1, MCM, CDC25, which are involved in cellular proliferation and cell
cycle [80]. Many studies demonstrated that YAP, along with the transcriptional coactivator
with PDZ-binding motif (TAZ), regulates cell cycle, invasion, migration, and EMT [81]
(Figure 1).
4.6. Cervical Cancer
miR-345 was upregulated in cervical cancer (CC) and studied by Cheung et al.
(Figure 1). They studied the distinct miRNA expression signatures for cervical intraepithelial neoplasia (CIN) and normal cervical epithelium. Out of the 202 miRNAs evaluated,
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12 were highly differentially regulated miRNAs, including miR-518a, miR-34b, miR-34c,
miR-20b, miR-338, miR-9, miR-512-5p, miR-424, miR-345, miR-10a, miR-193b, and miR203. Seven of these twelve miRNAs (miR-9, miR-20b, miR-345, miR-338, miR-518a, and
miR-512-5p) were upregulated, and miR-203 was downregulated, showing a significantly
different expression in cervical SCC, compared to normal epithelium. These dysregulated
miRNAs mainly controlled the apoptosis signaling pathways and cell cycle regulation [82].
4.7. Breast Cancer
The role of miR- 345 in breast cancer (BRCA) was noted in Pogribny et al., which
was an investigation of the cisplatin-resistant acquisition phenotype, where miRNA alterations in the MCF-7 human breast adenocarcinoma cells were studied. They identified a
total of 103 miRNAs that were differentially expressed (46 upregulated and 57 downregulated) in MCF-7 cells resistant to cisplatin. The most significantly dysregulated miRNAs
were miR-146a, miR-10a, miR-221/222, miR-345, miR-200b, and miR-200c. miR-345 in
breast cancer was downregulated, helping in cisplatin-resistant phenotype acquisition.
These differentially expressed miRNAs are involved in controlling cell signaling, cell
survival, DNA methylation, and invasiveness. Further, they also demonstrated that miR345 targets the human multidrug resistance-associated protein 1 (ABCC1/MRP1). These
suggest that the dysregulated miRNA expression is critically associated with the cisplatinresistant phenotype [83,84] (Figure 1). Ulasov et al. recently showed possible functional
interactions between KISS1, E-cadherin, and miR-345. The tumor microenvironment, which
controls breast cancer spreading via miR-345-regulated KISS1 expression, might modulate
metastatic spreading via a mechanism involving the upregulation of E-cadherin production [85] (Figure 1). Thus, miR-345 has a predominant role in breast cancer and could be a
great therapeutic target.
4.8. Oral Carcinoma
The potential role of miRNAs has been well documented in the pathogenesis and
progression of oral squamous cell carcinoma (OSCC). The role of miR-345 was initially
studied by Cervigne et al., showing 109 miRNAs were highly expressed, exclusively
in progressive invasive OSCC. Among the 109 miRNAs, three miRNA (miR-21, miR181b, and miR-345) expressions were consistently increased and associated with increased
lesion severity during progression. Overexpression of these three miRNAs may, therefore,
play an important role in the malignant transformation. Further, miR-345 expression
was increased, indicating it might play a critical role in the malignant transformation of
oral carcinoma. They also observed the upregulated miR-345 had no significant role in
pathogenesis of OSCC [86,87]. The recent study by Wu et al. showed contradictory results
to the above study’s statement, evidencing that the expression levels of miR-345 were
downregulated in OSCC tissues, compared to normal tissue, and highlighting miR-345
as a tumor suppressor in OSCC [88]. The cell proliferation and cell cycle arrest at the G1
phase, exhibited by miR-345, are similarly observed in other cancerous conditions reported.
The in silico and in vitro data showed a miR-345 binding site at the 30 UTR of ZEB2, and
an inverse correlation between miR-345 and ZEB2 mRNA expression was reported in
OSCC [88] (Figure 1). The general role of ZEB2 is as a DNA-binding transcription factor
that contributes to a series of cellular functions, such as cell proliferation and colony
formation, as well as migration, invasion, and tumor cell-induced angiogenesis [89]. ZEB
is also known as a transcriptional repressor of E-cadherin in cancer, thereby facilitating
EMT in breast and colon carcinoma. ZEB also helps in tumor angiogenesis via the TGFβ signaling cascade [90,91]. Elevated ZEB2 expression leads to poor outcomes in other
cancers like breast cancer, ovarian cancer, oral squamous cell carcinoma, and PC [92,93].
4.9. Mesothelioma
Malignant mesothelioma (MM) is an aggressive type of cancer that arises from
mesothelial cells, mainly due to former asbestos exposure. Guled et al. demonstrated that
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miR-345 was shown to be highly expressed in malignant mesothelioma, compared with
normal samples (Figure 1). They assessed eleven miRNAs (let-7b*, miR-1228*, miR-195*,
miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p),
which were highly expressed. Nine others (let-7e*, miR-144*, miR-203, miR-340*, miR-34a*,
miR-423, miR-582, miR-7-1*, and miR-9) were unexpressed or had severely reduced expression levels. These miRNAs target genes are primarily affected in MM, including CDKN2A,
NF2, JUN, HGF, and PDGFA [94].
4.10. Acute Myeloid Leukemia
The study conducted by Ying et al. shows that miR- 345 expression was significantly
lower in acute myeloid leukemia (AML) patients, when compared to normal patients,
helping in AML cell proliferation. AML is a malignant hematopoietic disease, which is
caused by abnormalities in the hematopoietic stem cell. Further in silico analysis revealed
that AKT1/AKT2 are the targets of miR-345. AKT1/2 was negatively correlated with
miR-345-5p expression and was responsible for apoptosis and cell proliferation [95]. They
also found out that expression levels of miR-345 were decreased in both in vitro and
in vivo; when they overexpressed miR-345, they observed cell cycle arrest at the G0/G1
phase and, thus, reduced cell proliferation. Further, the study identified the PI3K/AKT
signaling pathway as a critical pathway for the malignancy, providing new insight into
AML treatment, diagnosis, and prognosis for translational research. AKT signaling was
previously reported to be crucial in leukemia cell proliferation, and the PI3K/AKT/mTOR
pathway is important in AML evolution and relapse [96]. Thus, targeting the AKT signaling
pathway may provide a new avenue for leukemia treatment [97]. PI3K activation can
phosphorylate its downstream AKT. Further, AKT affects its downstream cascades, such as
CREB and mTOR [98].
4.11. Anaplastic Thyroid Carcinoma
A study conducted by Marini et al. showed that anaplastic thyroid carcinoma (ATC)and papillary thyroid carcinoma (PTC)-derived cell lines, along with their tissue samples,
showed a differential expression of multiple miRNAs, in which miR-345 showed a significant downregulation [99] (Figure 1).
4.12. Lip Cancer
The study conducted by Assao et al., to check expression levels of miR-181b, miR-21,
miR-31, and miR-345 in actinic cheilitis with and without epithelial dysplasia and with
lower lip squamous cell carcinomas (LLSCC), revealed that increased expression of miR345, miR-181b, and miR-31 was found in actinic cheilitis without epithelial dysplasia, in
comparison with that of actinic cheilitis with epithelial dysplasia and LLSCC (Figure 1).
Thus, this miRNA signature can help to identify actinic cheilitis, with the potential to
progress to lip cancer [100].
4.13. Glioblastoma
A study by Cao et al. on glioblastoma (GBM) suggested that long non-coding RNA
(lncRNA) LINC01426 plays an important role in the progression of glioblastoma by downregulating miR-345-3p, thus upregulating VAMP8, which helps in cell proliferation (in
silico analysis showed VAMP8 as potential target of miR345-3p). In addition, they also
found that, when miR345-3p inhibitor was used and VAMP8 was overexpressed, they could
partly rescue the cell proliferation inhibition by knockdown of LINC01426 in U251 GBM
cells. Thus, their findings suggested that any of the deregulation in the LINC01426/miR3453p/VAMP8 axis promotes GBM development [101] (Figure 1). miRNA can interfere with
LncRNA and its downstream pathway as ceRNA, affecting its post-transcriptional regulation [102]. Competing endogenous RNAs (ceRNA) regulate other RNA transcripts,
by competing for shared miRNA and regulatory networks, and are generally involved
in different biological processes of cancer, such as tumorigenesis, EMT, and metastasis
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cascades [103]. The interaction between lncRNA-miRNA functional networks has been
a new area of attraction in recent years. It is still unclear from this study as to whether
LINC01426 binds to miRNA to regulate GBM development, and what the mechanisms
behind why LINC01426 is elevated in GBM are. Here, we have summaried the role of
miR-345 in various malignancies in Table 1.
Table 1. Denotes the role of MiRNA-345 in different cancers.
Section No.

Cancer Type
1.

2.
1

Pancreatic
(PC, PDAC)

3.

4.
5.

1.

2

Colon and
Rectal
(CRC, LARC)

2.
3.

1.

3

Gastric (GC)

2.
3.

1.
2.
4

Prostate
(PCa, CRPC)
3.

1.
5

Lung (NSCLC)

miR345
Target(s)

References

Disruption of mitochondrial membrane
potential, resulting in caspase-dependent
apoptosis.
Mediation of anti-apoptotic BCL2 in
caspase-independent apoptosis.
Overexpression evidenced increased
gemcitabine cytotoxicity, increased epithelial
markers, and decreased mesenchymal markers.
Inactivation of NFkB signaling by targeting
CCL8 and downstream inflammation response.
Downregulation of MUC4 and SHH impacting
EMT.

BCL2
CCL8

[41,42,49]

Strong prognostic marker for overall survival
and response to cetuximab/irinotecan
treatment in mCRC.
Implicated as methylation-sensitive miRNA,
with a possible role in CRC growth inhibition.
High expression associated with
chemoradiotherapy resistance.

BAG3

[37,59,60]

Low expression implicated in lymph
metastasis, advanced GC stage, reduced
overall, and disease-free survival.
Knockdown evidenced aggressive phenotype
and EMT.
Prevents tumor metastasis and EMT by
targeting FOXQ1.

FOXQ1

[63]

CDKN1A
Smad1

[68,69]

YAP1

[70,71]

miR345 Functional Role(s)

2.

A diagnostic marker for PCa by circulating
miR-345-5p levels.
Inhibition of tumor cell cycle and eventual
tumor suppression, through
CDKN1A-mediated cyclin/CDK complex
inhibition.
Tumor progression inhibition via Smad1
targeting.

Inhibition of pro-tumoral YAP1 and
downstream prevention of tumor invasion and
metastasis.
Low expression associated with reduced
overall survival, malignant clinical parameters,
and poor prognosis.
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Table 1. Cont.
Section No.

miR345
Target(s)

References

High expression implicated in higher survival
rates.
Knockdown led to EMT through
IRF1-mediated mTOR/STAT3/AKT signaling
and downstream targeting of slug, snail, and
twist
Evidenced apoptotic inhibition in Huh7 cells
through p21 targeting.
Upregulation of HBV replication levels, leading
to HCC cell proliferation.
YAP1 and YAP/TAZ-related role in EMT,
tumor progression and metastasis.
Knockdown evidenced more significant HCC
lung metastasis.

p21
IRF1
YAP

[40,73–75,78]

Upregulation evidenced in CIN versus normal
epithelium.
Associated with apoptotic signaling and cell
cycle regulation.

N/A

[82]

ABCC1
KISS1

[83–85]

High expression associated with increased
lesion severity and progressive invasive OSCC
phenotype.
Downregulated in OSCC tissue versus normal
samples.
Implicated in ZEB2 suppression through an
inverse expression relationship.

ZEB2

[86–88]

1.

Upregulation evidenced in MM tissue versus
normal samples.

N/A

[94]

1.

Implicated in cell proliferation and apoptosis
via AKT1/AKT2 targeting.
Overexpression induced G0/G1 arrest, leading
to decreased tumor proliferation.
Downregulated in AML versus normal
samples.

AKT1/
AKT2

[95]

Downregulated in ATC tissues versus normal
samples.

N/A

[99]

Cancer Type

miR345 Functional Role(s)
1.
2.

6

Liver (HCC)

3.
4.
5.
6.

1.
7

Cervical
(CC, CIN)

2.

1.
8

Breast (BRCA)

2.

1.

9

Oral (OSCC)

2.
3.

10

11

12

Mesothelioma
(MM)

Acute Myeloid
Leukemia
(AML)

Anaplastic
Thyroid
Carcinoma
(ATC)

2.
3.

1.

Downregulation associated with
cisplatin-resistant phenotype, possibly via
targeted ABCC1.
Implicated in brain metastasis by KISS1 and
E-cadherin signaling.
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Table 1. Cont.
Section No.

Cancer Type

13

Lip Cancer
(LLSCC)

14

Glioblastoma
(GBM)

miR345 Functional Role(s)
1.

Downregulation evidenced in LLSCC versus
actinic cheilitis samples.

1.
2.

Downregulated in GBM versus normal samples
Implicated in regulation of VAMP8, a cell
proliferation-facilitating protein.

miR345
Target(s)

References

N/A

[100]

VAMP8

[101]

Figure 1 below summarizes the mechanistic approach of miR-345 in pancreatic cancer,
along with various other cancers.
5. miRNA Nanodelivery
Despite promising studies showing the potential for the use of miRNA as therapeutics,
current clinical applications of miRNA are few, including only two clinical trials. The first
is a phase 1 trial using INT 1B3, a lipid nanoparticle formulation of miR-193s-3p, to treat
advanced solid tumors [104]. The second is a phase 1 and 2 trial using AMT-130, an
adeno-associated viral vector expressing miHTT, to treat Huntington’s disease [105]. Given
the lack of phase 3 clinical trials and the broad range of potential applications of miRNA
treatments, it remains undetermined as to what the optimal delivery methods will be.
Successful delivery of miRNA to target sites, including PC, presents many challenges.
These challenges include stability, transport, diffusion, off-target effects, cellular entry, and
endosomal escape [106]. Naked miRNA is easily degradable by nucleases, causing poor
stability in the blood-stream and reduced circulation half-life, thus leading to unfavorable
pharmacokinetics [107]. Naked miRNA lacks the ability to specifically target a desired cell
type or location in the body; this nonspecific targeting results in off-target toxicity and poor
bioavailability, as well. The phosphate groups in naked miRNA impart a negative charge,
which creates difficulty in penetrating cell membranes, due to electrostatic repulsion.
miRNA also degrades in the low pH environments found in endosomes. When the naked
miRNA is successfully taken in by target cells via endocytosis, it can be degraded in the
endosome, before being released into the cytoplasm.
Viral vectors and nanoparticles can be used as delivery vehicles for miRNA to address
these previously mentioned challenges. The main goals of the nanodelivery systems are to
protect the miRNA from degradation, efficiently transport the miRNA to the target site, and
facilitate cellular uptake and endosomal escape. While viral vectors are generally highly
efficient in transduction, the major disadvantage of viral vectors is that they are highly
immunogenic [108]. Non-viral vectors, in the form of nanoparticles, are much more biocompatible and are tunable in physicochemical properties. Nanoparticle delivery vehicles
with a positive charge can either electrostatically complex or encapsulate the negatively
charged miRNA. Electrostatic complexation protects the miRNA from degradation and
shields the negative charges. Low encapsulation efficiency is common in the delivery of
miRNAs, which is often due to the encapsulation method or biomaterial chosen as the
delivery system [109]. Different biomaterials have been investigated for the nanodelivery
of miRNA for cancer treatment, including liposomes/lipids [110,111], polymers [112,113],
and inorganic nanoparticles [114]. An important aspect of these nanoparticles is their
ability to deliver small molecule drugs, in combination with miRNA, to synergistically treat
PC and potentially increase the efficacy of the treatment. Additionally, each of these types
of nanoparticles can be surface-modified for targeted delivery, which will be discussed
later. Liposomes, such as LipofectamineTM , are biocompatible, with generally low toxicity.
They are also amphiphilic, which can be an advantage for the combination delivery of
drugs and miRNA. Inorganic nanoparticles have the advantage of being highly stable and
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biologically inert. However, they are not biodegradable and other biomaterials, such as
polymers or lipids, are typically needed to allow for the desired chemical attachments
or electrostatic complexation with miRNAs. Polymers, on the other hand, are tunable
in size, molecular weight, surface charge/groups, and morphology, which controls their
biodegradability, biocompatibility, specific targeting, and overall efficiency as nanodelivery systems. Nanoparticles of biodegradable polymers are also good candidates for the
sustained release of miRNA and drugs.
Targeting strategies increase the accumulation of the miRNA at the target site. A broad
range of biological ligands can be attached to the nanoparticle surface to bind to specific
target cell receptors. These ligands could include proteins, antibodies, or polysaccharides,
among other biological molecules [115]. Stimuli responsiveness can also be a form of
targeting. Differences in the physicochemical properties of the target site, such as pH or
hypoxia, in PC and other cancers, can be leveraged to trigger the release of the miRNA from
the delivery system. For example, Gupta et al. (2018) developed a pH-responsive, silicasupported mesoporous titania nanocarrier to deliver paclitaxel and miR-708 for colorectal
carcinoma, which showed a significantly higher release at low pH [116]. In addition to
target site specificity, the rate of miRNA release is important for maintaining a therapeutic
concentration at the target site.
The sustained release of therapeutic miRNAs could prevent the need for multiple
doses to be administered. The controlled release of miRNA is possible with polymer
nanoparticles as the delivery vehicle. Arora et al. developed PLGA-based nanoparticles
to deliver miR-150 to PC, which showed a sustained release over 14 days [117]. The rate
of release can be tuned by altering the monomers, methods of polymerization, and encapsulation [118]. Changing the size, surface charge, and degree of hydrophobicity are
also important in drug delivery for maximizing the circulation time and cellular uptake
of the nanoparticle [119]. Hydrophobic nanoparticles are more easily recognized by the
reticuloendothelial system and removed from circulation, decreasing the bioavailability [119]. Highly charged nanoparticles have also been shown to lead to removal from
circulation and can also exhibit enhanced cytotoxicity [120]. The ideal size for nanoparticles is dependent on the target site [119]. For example, the enhanced permeation and
retention effect in tumors can be leveraged by keeping the nanoparticle diameter between
10–100 nm to increase accumulation in the tumor microenvironment [121]. Non-biodegradable
nanoparticles need to be under 17 kDa in molecular weight to be cleared by the kidneys
and excreted [122].
Few systems have been developed for the co-delivery of miRNA and chemotherapeutic drugs for the treatment of PC. These systems aim to provide a synergistic anticancer
effect in treating PC with miRNAs and drugs. Figure 2 summarizes the methods for
delivery of miRNA and drugs, using viral vectors and nanoparticles.
miR-205, miR-345, and miRlet-7b have all been used in combination delivery systems for PC treatment. miR-205 and gemcitabine were delivered using a cationic copolymer,
poly(ethyleneglycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanolgraft-cationic ligands) (mPEG-b-PCC-g-GEM-g-DC-g-CAT) [113]. A film hydration method
was used to form polyplexes containing gemcitabine and miR-205. Significant tumor reduction was seen in the in vivo study on ectopic tumors in athymic nude mice, when treated
with these polyplexes [113]. A micellar formulation of poly(ethylene glycol)-block-poly(2methyl-2-carboxyl-propylene carbonate-graft-dodecanol-graft-tetraethylenepentamine)
(PEG-b-PCC-g-DC-g-TEPA) was used to deliver miR-let7b and hedgehog inhibitor GDC0449 in an orthotopic PC mouse model [123]. These micelles, containing miR-let7b and
GDC-0449, were also formed by film hydration. Significant tumor regression was seen in
the combined delivery group [123].
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Figure 2. Schematic overview of the production of nanodelivery vehicles, including viral vectors, polymeric nanoparticles,
inorganic nanoparticles, and liposomes, for miRNA and drug delivery. Created with BioRender.com.

For the delivery of miR-345 for PC treatment, we have developed a dual delivery
nanoscale device (DDND) that features several of the desired properties for miRNA
delivery, mentioned above, and synergistically transports miR-345, as well as gemcitabine to PC cell lines and in vivo mouse models [22]. The DDND is composed of a
temperature- and pH-responsive pentablock copolymer, electrostatically complexed with
miR-345 and gemcitabine-encapsulated Pluronic F127 micelles. The pentablock copolymer
consists of a Pluronic F127 middle block (poly(ethyleneoxide)-block-poly(propyleneoxide)block poly(ethyleneoxide) (PEO-PPO-PEO)) with poly (2-diethylaminoethyl methacrylate
(PDEAEM) end blocks. The Pluronic F127 middle blocks are temperature-responsive, while
the PDEAEM end blocks are cationic and pH-responsive. The cationic PDEAEM end blocks
allow for electrostatic complexation of miR-345. The temperature-responsive middle blocks
allow for temperature-dependent gelation at near body temperatures, allowing for a gene
and drug depot and sustained release. The pH sensitivity of the polymer is tuned to enable
endosomal escape easily in cancer cells but not in normal cells, allowing for the targeting of
cancer cells [124]. These DDND showed very high encapsulation efficiencies of miRNA and
good serum and RNase stability. Increased transfection efficiency was also seen, compared
to the commercially available transfection agent, LipofectamineTM [22].
6. Conclusions
This review cultivates the hypothesis on how miR-345 plays a vital role as a prognostic
and therapeutic target and surveys effective ways to deliver to the targeted sites in PDAC
and various other cancer types. The limitations of current treatment strategies in PC
reinforce the need for new avenues of research to be explored, in order to achieve potential
breakthroughs. Significant gaps remain in the understanding of this disease; although the
treatment options are continually evolving, they still have had limited success. There has
been a recent drive to fund large consortia and specialist research into pancreatic ductal
adenocarcinoma, but there is much work to be done to enable similar breakthroughs, as
seen for other cancer types. In this review, we emphasized the role of miR-345 in different
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cancers, with a particular interest in PDAC and its effective miRNA nanodelivery for
successful therapeutic application, as miRNA delivery will be the potential key for the
successful treatment of cancers in the future.
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